Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
Last trade$25.44
Day change+$0.005 (+0.02%)
Day range$24.11 – $25.66
Volume146,297
Market cap$790M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$790.25M
Price / earnings
20.71×
Price / book
2.67×
Price / sales
0.97×
EV / sales
2.12×
EV / EBITDA
4.82×
Profitability
Earnings per share
$1.23
Return on assets
1.82%
Return on equity
12.88%
Dividend yield
0%
Liquidity and leverage
Debt / equity
3.65×
Current ratio
1.01×
Quick ratio
0.87×
Cash ratio
0.24×
Cash flow
Price / cash flow
2.34×
Price / free cash flow
2.35×
Free cash flow
$336.29M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for COLL, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$216.34M
$199.88M
$193.52M
$205.45M
$209.36M
$188M
$177.76M
$181.95M
Cost of revenue
$90.92M
$26.63M
$20.8M
$77.07M
$80.19M
$24.14M
$24.96M
$83.66M
Gross profit
$125.42M
$173.25M
$172.72M
$128.38M
$129.17M
$163.86M
$152.8M
$98.29M
Selling, general and administrative
$99.59M
$106.59M
$86.35M
$67.64M
$67.1M
$73.64M
$76.42M
$63.09M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$96.7M
$169.55M
$141.82M
$66.46M
$67.08M
$128.75M
$131.9M
$60.18M
Operating income
$28.72M
$3.7M
$30.9M
$61.92M
$62.09M
$35.11M
$20.9M
$38.11M
Interest expense
-$21.94M
-$19.52M
-$15.86M
-$19.29M
-$21.77M
-$20.46M
-$20.79M
-$22.65M
Income before taxes
$7.91M
-$13.53M
$18.74M
$29.04M
$43.44M
$17.03M
$3.12M
$17.27M
Income taxes
-$13.85M
$1.52M
$4.24M
$12.07M
$11.93M
$5.04M
$705K
$4.73M
Net income
$21.76M
-$15.05M
$14.5M
$16.96M
$31.51M
$11.98M
$2.42M
$12.54M
Net income attributable to common shareholders
$21.76M
-$15.05M
$14.5M
$16.96M
$31.51M
$11.98M
$2.42M
$12.54M
EBITDA
$84.56M
$68.46M
$86.83M
$118.32M
$118.59M
$91.71M
$77.47M
$94.62M
Basic earnings per share
$0.69
-$0.46
$0.45
$0.54
$1.00
$0.38
$0.08
$0.39
Diluted earnings per share
$0.60
-$0.46
$0.40
$0.36
$0.84
$0.34
$0.07
$0.32
Recent news
Company coverage with links to the original publishers.
uniQure's lead gene therapy candidate, ifezuntirgene inilparvovec, for Huntington's disease has received FDA Priority Review with a May 1, 2027 decision date. The company plans to launch a confirmatory study by end of 2026 targeting 200 patients. While the regulatory milestone drove a 17.5% stock surge, mixed clinical data, widening loss estimates, and pipeline risks temper the outlook. The company maintains a strong cash position of $768.4 million expected to fund operations through 2030.
Nektar Therapeutics reported a Q3 2026 loss of $1.63 per share, beating consensus estimates, but revenues fell 20.4% year-over-year to $9.4 million. The company cut full-year 2026 revenue guidance to $38 million from $40-$45 million and reduced R&D spending guidance. All three Phase III ZENITH AD studies for its lead candidate rezpeg are underway, with initial data expected in summer 2028.
Liquidia Corporation (LQDA) reported strong Q3 2026 results with earnings of 80 cents per share and revenues of $225.3 million, driven by Yutrepia sales of $222.7 million. However, a $389.7 million litigation settlement with United Therapeutics restricts Yutrepia's promotion to pulmonary arterial hypertension only, eliminating PH-ILD commercialization. The company maintains confidence in PAH growth and has sufficient cash reserves to support settlement payments and pipeline expansion.
Mirum Pharmaceuticals announced positive results from the Phase III AZURE-4 study for brelovitug, an investigational treatment for chronic hepatitis delta virus (HDV). The drug met its primary endpoint with 59% and 44% response rates across two dosing regimens versus 0% for delayed treatment. Combined with positive AZURE-1 data, these two studies will support a U.S. BLA filing in the first half of 2027, with potential commercial launch expected in Q4 2027.
TG Therapeutics reported Q3 2026 EPS of 35 cents and revenues of $259.9 million, both beating consensus estimates. Briumvi U.S. sales surged 52% to $232.6 million driven by physician adoption and patient growth. The company raised its 2026 global revenue guidance to $1 billion and expects Q4 U.S. Briumvi sales above $260 million. The stock rose 5.9% following the results.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.